Last reviewed 2026-04-20 · How we verify

Aprecon (ISOAMINILE)

Phase 2 active Small molecule

Aprecon (generic name: ISOAMINILE) is a isoaminile drug. It is currently in Phase 2 development.

Aprecon works by interacting with a specific molecular target to produce a therapeutic effect.

Aprecon, also known as Isoaminile, is a small molecule drug of the isoaminile class. Its original development is attributed to an unknown entity, and its current ownership is also unclear. The target and indications for Aprecon are not specified, and its commercial status, including FDA approval and patent status, is unknown. Aprecon's pharmacokinetic properties, such as half-life and bioavailability, are also not documented. Further research is necessary to understand the drug's clinical profile and safety considerations.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ISOAMINILE
Drug class	isoaminile
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Aprecon has a key that fits into those locks. When Aprecon binds to its target, it helps to regulate the activity of the cells, leading to a therapeutic effect. This process is crucial for treating various diseases, but the exact mechanism of Aprecon is not well understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Aprecon CI brief — competitive landscape report
Aprecon updates RSS · CI watch RSS

Frequently asked questions about Aprecon

What is Aprecon?

Aprecon (ISOAMINILE) is a isoaminile drug.

How does Aprecon work?

Aprecon works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Aprecon?

ISOAMINILE is the generic (nonproprietary) name of Aprecon.

What drug class is Aprecon in?

Aprecon belongs to the isoaminile class. See all isoaminile drugs at /class/isoaminile.

What development phase is Aprecon in?

Aprecon is in Phase 2.

Drug class: All isoaminile drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing